封面
市場調查報告書
商品編碼
2147371

女性健康及婦科超音波診斷設備市場:維持並擴大收入基礎,2024-2035年

Women's Health and OB/GYN Ultrasound Market: Defending and Extending the Revenue Pool, 2024A-2035E

出版日期: | 出版商: Marketstrat, Inc. | 英文 41 Pages | 訂單完成後即時交付

價格

報告摘要

這份 Marketstrat® 重點報告評估了全球婦產科和女性健康超音波市場,以2024年為基準年,預測期至2035年。本報告計算了供應商的收入資料,並分析了其與臨床需求、醫療保健服務環境、產科人工智慧和家庭監督使用之間的相關性。

我們的觀點:首先,我們應該與客戶保持良好的關係,包括設備更換和維護契約,然後透過專門的探測、報告服務和付費人工智慧服務來增加每位客戶的收入。

需要解答的關鍵問題

  • 隨著女性健康領域在整個超音波市場中所佔佔有率的下降,供應商如何增加價值?
  • 從早期妊娠的詳細解剖檢查到不孕症監測,哪些工作流程需要使用高階系統和一般軟體?
  • 哪些通路將促成產科人工智慧作為付費服務獲得批准?
  • 居家產前超音波計畫要擴大規模,還需要證明什麼?

市場概覽

儘管女性健康領域仍是超音波診斷的第三大臨床應用領域,且其絕對值持續成長,但由於循環系統和急診領域的快速發展,其佔有率下降。區域和國別比較凸顯了成熟市場設備更換和工作流程驅動型支出與印度在擴大超音波診斷應用方面更大機會之間的差異。

主要市場趨勢

  • 1.高階平台的部署日益擴大。隨著三星和飛利浦在2026年9月推出新產品,婦產科和早期懷孕工作流程領域的競爭加劇。
  • 2.產科人工智慧正日益整合到掃描器中。雖然OEM市場和整合協定日益擴大現有部署平台的存取權限,但付費部署仍是另一項挑戰。
  • 3.雖然診所是重要的銷售管道,但買家的需求並不統一。胎兒醫學專家所需的系統、支援和資金籌措結構與小規模綜合診所截然不同。
  • 4.家庭監測是一項「路徑」業務。美國批准的用途僅限於特定的處方用途,該項目是否擴展取決於贊助商的資金和臨床醫生的評估。

目錄

執行摘要

  • 三個重要的數值
  • 至2026年9月的變化
  • 為決策者提供的見解

第1章 引言和範圍

  • 業務挑戰
  • 包含對象和不包含對象
  • 數值讀法

第2章 池:規模與預測(2024A–2035E)

  • 全球供應鏈及其佔有率的趨勢
  • 臨床需求為供應商創造價值
  • 在應用結構中對女性健康的定位
  • 區域和國家層面的市場比較

第3章 需求結構:臨床需求、醫療服務環境與供應商經濟

  • 人口背景與收入機制
  • 以診所為基礎的照護作為一種成長管道
  • 五項臨床准入機會
  • 對勞動力、檢測品質和證據的要求

第4章 人工智慧在女性健康中的作用

  • 為人工智慧在女性健康領域的商業化做好準備
  • 臨床功能、介紹和所有權
  • 法規、產品和夥伴關係的歷史沿革
  • 如何將產科人工智慧商業化

第5章 居家監控:償付制度出現之前的經營模式

  • 此類別是
  • 大規模採用的五個要件
  • 專用程式和相關平台

第6章 競爭環境及要點

  • OEM女性健康業務
    • GE HealthCare
    • Samsung Medison
    • Mindray
    • Philips
    • 其他 OEM 和共享服務選項
  • 關於產科人工智慧和報告產生的關鍵點。
    • Sonio(Samsung Medison)
    • BrightHeart
    • Diagnoly
    • Biotics AI、DeepEcho 和 Ultrasound AI
    • AS軟體和企業彙報
  • HOME與存取焦點
    • Pulsenmore
    • Butterfly Network
  • 競爭分析

第7章 平台經濟學與購買模式

  • 硬體整合
  • 購買模型和診所
  • 乳房攝影診斷中共用平台的經濟學

第8章 截至2026年9月10日的趨勢

  • 已報告的財務狀況
  • 監管、產品、政策和資本趨勢

第9章 影響及建議措施

  • OEM女性健康業務
  • 獨立婦產科醫師人工智慧供應商
  • 家庭監控與存取平台
  • 投資者和企業發展
  • 醫療保健提供者和醫療保健系統

第10章 顯著徵兆與情景

  • 市場概況

第11章 調查方法、資訊來源與解釋

  • 模型基礎
  • 資訊來源
  • 調查縮短和報告期間的時間安排
  • 限制

附錄A. 依地區和國家分類的婦產科估計資料。

附錄B. 主要參考文獻

Product Code: MINTF-02105-08

Report Overview

This Marketstrat® Focus Report assesses the global OB/GYN and women's health ultrasound market from a 2024A base through 2035E. It sizes supplier revenue and links it to clinical demand, care settings, obstetric AI and supervised home use.

Our view: defend replacement and service relationships first, then earn more per account through specialty transducers, reporting and paid AI.

Key Questions Answered

  • How can suppliers capture incremental value while women's health loses share of total ultrasound revenue?
  • Which workflows, from detailed first-trimester anatomy to fertility monitoring, justify premium systems or recurring software?
  • Which distribution route turns OB-AI clearances into paid adoption?
  • What must a home prenatal ultrasound program prove before it can scale?

Market Snapshot

Women's health remains ultrasound's third-largest clinical application and grows in absolute terms, even as faster growth in cardiology and acute care lowers its share. Regional and country comparisons contrast replacement- and workflow-led spending in mature markets with a larger access-expansion opportunity in India.

Key Market Trends

  • 1. Premium platforms are broadening. September 2026 launches from Samsung and Philips extend competition into maternal, gynecologic and early-pregnancy workflows.
  • 2. Obstetric AI is moving onto the scanner. OEM marketplace and integration agreements widen access to the installed base; paid rollout remains a separate test.
  • 3. The office is a priority channel, though not a uniform buyer. Fetal-medicine specialists and small general clinics need very different systems, support and financing.
  • 4. Home monitoring is a pathway business. US authorization covers a defined prescription use; sponsor funding and clinician review decide whether programs scale.

Competitive Structure

The report profiles the dedicated women's health franchises of GE HealthCare (Voluson), Samsung Medison (HERA) and Mindray (Nuewa), plus Philips and shared-service rivals. Spotlights cover OB-AI and reporting developers such as Sonio, BrightHeart, Diagnoly and AS Software; Pulsenmore and Butterfly Network anchor the home section. A roles table sets each participant's execution priority.

What's Inside

Sizing and scenarios: Global pool, application, care-setting and hardware views, with downside, base and upside cases to 2035E.

AI readiness: An ARC-Index assessment by use case, a regulatory and partnership chronology through September 2026, and how OB AI gets paid.

Home monitoring: Status of the five requirements for scaling US home prenatal ultrasound.

Actions and signals: Recommendations by participant group and eight signals to watch over the next 12–24 months.

Who Should Read This Report

  • Ultrasound OEM executives and women's health product managers
  • Leaders of obstetric AI, reporting and home-monitoring companies
  • Investors and corporate-development teams evaluating the category
  • Health systems and OB/GYN practices planning equipment or AI purchases
  • Fertility clinics considering home follicle monitoring

Why This Report

Most coverage stops at launches and clearance counts. This report ties those events to the revenue a supplier can book and separates regulatory decisions from company announcements. Recommendations are staged against observable commercial milestones.

Table of Contents

EXECUTIVE SUMMARY

  • THE THREE NUMBERS THAT MATTER
  • WHAT CHANGED THROUGH SEPTEMBER 2026
  • IMPLICATIONS FOR DECISION-MAKERS

1. INTRODUCTION AND SCOPE

  • 1.1 THE COMMERCIAL QUESTION
  • 1.2 WHAT IS IN AND WHAT IS OUT
  • 1.3 HOW TO READ THE NUMBERS

2. THE POOL: SIZING AND FORECAST, 2024A TO 2035E

  • 2.1 THE GLOBAL POOL AND ITS SHARE DRIFT
  • 2.2 WHERE CLINICAL DEMAND CREATES SUPPLIER VALUE
  • 2.3 WHERE WOMEN’S HEALTH SITS IN THE APPLICATION MIX
  • 2.4 REGIONAL AND COUNTRY MARKET COMPARISONS

3. DEMAND ARCHITECTURE: CLINICAL NEED, CARE SETTINGS AND SUPPLIER ECONOMICS

  • 3.1 DEMOGRAPHIC CONTEXT AND THE REVENUE MECHANISM
  • 3.2 OFFICE-BASED CARE AS A GROWTH CHANNEL
  • 3.3 FIVE CLINICAL AND ACCESS OPPORTUNITIES
  • 3.4 LABOR, EXAM QUALITY AND EVIDENCE REQUIREMENTS

4. THE AI LAYER IN WOMEN’S HEALTH

  • 4.1 COMMERCIAL READINESS OF WOMEN’S HEALTH AI
  • 4.2 CLINICAL FUNCTION, DEPLOYMENT AND OWNERSHIP
  • 4.3 REGULATORY, PRODUCT AND PARTNERSHIP CHRONOLOGY
  • 4.4 HOW OB AI GETS PAID

5. HOME MONITORING: A PATHWAY BUSINESS AHEAD OF REIMBURSEMENT

  • 5.1 WHAT THE CATEGORY IS
  • 5.2 FIVE REQUIREMENTS FOR SCALABLE ADOPTION
  • 5.3 PURPOSE-BUILT PROGRAMS AND ADJACENT PLATFORMS

6. COMPETITIVE SET AND SPOTLIGHTS

  • 6.1 OEM WOMEN’S HEALTH FRANCHISES
    • GE HealthCare
    • Samsung Medison
    • Mindray
    • Philips
    • Other OEM and shared-service alternatives
  • 6.2 OB-AI AND REPORTING SPOTLIGHTS
    • Sonio (Samsung Medison)
    • BrightHeart
    • Diagnoly
    • Biotics AI, DeepEcho, and Ultrasound AI
    • AS Software and enterprise reporting
  • 6.3 HOME AND ACCESS SPOTLIGHTS
    • Pulsenmore
    • Butterfly Network
  • 6.4 COMPETITIVE READ

7. PLATFORM ECONOMICS AND PURCHASE MODELS

  • 7.1 THE HARDWARE LINKAGE
  • 7.2 PURCHASE MODELS AND THE OFFICE
  • 7.3 SHARED-PLATFORM ECONOMICS WITH BREAST IMAGING

8. DEVELOPMENTS THROUGH SEPTEMBER 10, 2026

  • 8.1 REPORTED FINANCIAL CONTEXT
  • 8.2 REGULATORY, PRODUCT, POLICY, AND CAPITAL DEVELOPMENTS

9. IMPLICATIONS AND RECOMMENDED ACTIONS

  • 9.1 OEM WOMEN’S HEALTH FRANCHISES
  • 9.2 INDEPENDENT OB-AI VENDORS
  • 9.3 HOME-MONITORING AND ACCESS PLATFORMS
  • 9.4 INVESTORS AND CORPORATE DEVELOPMENT
  • 9.5 PROVIDERS AND HEALTH SYSTEMS

10. SIGNALS TO WATCH AND SCENARIOS

  • 10.1 MARKET SCENARIOS

11. METHODOLOGY, SOURCES AND INTERPRETATION

  • 11.1 MODEL BASIS
  • 11.2 SOURCES
  • 11.3 RESEARCH CUTOFF AND REPORTING PERIODS
  • 11.4 LIMITATIONS

APPENDIX A. REGIONAL AND COUNTRY OB/GYN ESTIMATES

APPENDIX B. SELECTED SOURCE REFERENCES

List of Tables

  • TABLE 1: WOMEN’S HEALTH ULTRASOUND MARKET AND OFFICE-BASED CHANNEL CONTEXT, USD MILLION
  • TABLE 2: GLOBAL CLINICAL-APPLICATION MIX, SHARE AND USD MILLION
  • TABLE 3: REGIONAL OB/GYN REVENUE ESTIMATES, USD MILLION
  • TABLE 4: GLOBAL ALL-SPECIALTY END-MARKET MIX, SHARE AND USD MILLION
  • TABLE 5: WOMEN’S HEALTH AI: COMMERCIAL READINESS AND ADOPTION REQUIREMENTS
  • TABLE 6: SELECTED REGULATORY, PRODUCT AND PARTNERSHIP MILESTONES
  • TABLE 7: COMPETITIVE ROLES AND EXECUTION PRIORITIES
  • TABLE 8: ALL-ULTRASOUND SYSTEMS REVENUE BY HARDWARE SEGMENT, USD MILLION
  • TABLE 9: REPORTED FINANCIAL CONTEXT AND WOMEN’S HEALTH INTERPRETATION
  • TABLE 10: COMMERCIAL SIGNALS TO WATCH OVER THE NEXT 12–24 MONTHS
  • TABLE 11: WOMEN’S HEALTH ULTRASOUND MARKET SCENARIOS, 2035E
  • TABLE 12: REGIONAL AND COUNTRY OB/GYN REVENUE ESTIMATES, USD MILLION

List of Figures

  • FIGURE 1: GLOBAL OB/GYN AND WOMEN’S HEALTH ULTRASOUND REVENUE, 2024A, 2030E, AND 2035E
  • FIGURE 2: HOW CLINICAL DEMAND TRANSLATES INTO SUPPLIER REVENUE
  • FIGURE 3: GLOBAL ULTRASOUND CLINICAL-APPLICATION SHARES, 2024A AND 2035E
  • FIGURE 4: REGIONAL AND SELECTED-COUNTRY OB/GYN REVENUE ESTIMATES
  • FIGURE 5: WOMEN’S HEALTH ULTRASOUND: WORKFLOW, OWNERSHIP, AND DEPLOYMENT
  • FIGURE 6: US HOME PRENATAL ULTRASOUND: FIVE REQUIREMENTS FOR SCALE